Treatment Strategies in Relapsed Refractory Multiple Myeloma
Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.
EP: 1.Treatment Strategies in Relapsed Refractory Multiple Myeloma
EP: 2.Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma
EP: 3.KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 4.CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 5.Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma
EP: 6.Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma
EP: 7.Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy
EP: 8.Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma
EP: 9.Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
